Active, not recruitingPhase 2NCT02425904
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Studying Langerhans cell histiocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Barbara Degar, MDDana-Farber Cancer Institute
- Intervention
- Clofarabine(drug)
- Enrollment
- 25 enrolled
- Eligibility
- All sexes
- Timeline
- 2015 – 2026
Study locations (14)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of California San Francisco Medical Center, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Mount Sinai Medical Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- The Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
Sanofi · St. Baldrick's Foundation · Cookies for Kids' Cancer · North American Consortium for Histiocytosis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02425904 on ClinicalTrials.govOther trials for Langerhans cell histiocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07371182Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsWest China Second University Hospital
- RECRUITINGNANCT07431060Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisWest China Second University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT07204041Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE2NCT07022834Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenWest China Second University Hospital
- RECRUITINGPHASE2NCT07187193Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ENROLLING BY INVITATIONPHASE1NCT06902792Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsSecond Affiliated Hospital of Wenzhou Medical University
- RECRUITINGPHASE2NCT06582745Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibCook Children's Health Care System
- RECRUITINGPHASE2NCT05828069A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisNational Cancer Institute (NCI)